Valentina Boni, MD, PhD, on Breast Cancer Advances from 2022 ASCO


Valentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.

CancerNetwork® spoke with Valentina Boni, MD, PhD, of the Early Drug Development Unit at the Universitary Hospital Universitario Quirónsalud Madrid as well as director and principal investigator at NEXT Oncology Madrid in Spain, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about top trials in breast cancer.


2022 ASCO was a very interesting meeting, as always. The most important thing is that we had an opportunity to meet with other collaborative persons after more than 2 years. There are several other trials that are very interesting. The [phase 3] TROPiCS-02 [NCT03901339] with sacituzumab govitecan [Trodelvy] in patients with breast cancer that is hormone receptor–positive is a very important new trial, especially because it is a new antibody-drug conjugate that was previously approved in triple-negative breast cancer. It is going to be another standard of [care] therapy in hormone receptor–positive breast cancer.1,2

In the plenary session, the results of [phase 3] DESTINY-Breast04 trial [NCT03734029] were presented.3 The activity of trastuzumab deruxtecan [Enhertu] in patients with hormone receptor–positive/HER2-low breast cancer. That is going to be a new standard of care for these patients. We have a lot of new and interesting data, and some of them are going to change the clinical practice in metastatic breast cancer.


  1. Rugo HS, Bardia A, Marme F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol. 2022;40(suppl 17):LBA1001-LBA1001. doi: 10.1200/JCO.2022.40.17_suppl.LBA1001
  2. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. News Release. FDA. April 7, 2021. Accessed July 8, 2022.
  3. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content